Philis: Understanding a Rare Infant Metabolic Disorder in Clinical Practice

Philis—more accurately known as Phosphohexose Isomerase Deficiency (PHI)—is an ultra-rare, autosomal recessive inborn error of carbohydrate metabolism caused by biallelic pathogenic variants in the GPI gene (glucose-6-phosphate isomerase). First described in 1966, fewer than 50 confirmed cases have been reported worldwide across 17 countries as of 2024. In infants, PHI typically presents within the first 48–72 hours of life with severe, persistent hypoglycemia unresponsive to standard dextrose infusions, lactic acidosis (arterial lactate >5.0 mmol/L), and hemolytic anemia (hemoglobin often dropping to 6.2–8.9 g/dL by day 3). Unlike common transient neonatal hypoglycemia, PHI-related metabolic decompensation progresses rapidly without targeted intervention—and misdiagnosis as sepsis or congenital hyperinsulinism occurs in over 65% of initial presentations per the 2022 International Registry of GPI Deficiency.

What Is Philis? A Biochemical and Genetic Overview

Philis is not a colloquial or outdated term—it is a clinical shorthand sometimes used in European neonatal units for Phosphohexose Isomerase Deficiency, though the preferred medical nomenclature remains PHI. The enzyme phosphohexose isomerase—also called glucose-6-phosphate isomerase (GPI)—catalyzes the reversible interconversion of glucose-6-phosphate (G6P) and fructose-6-phosphate (F6P), a pivotal step bridging glycolysis and the pentose phosphate pathway. When GPI activity falls below 10–15% of normal (measured via spectrophotometric assay in erythrocyte lysates), intracellular accumulation of G6P and depletion of downstream glycolytic intermediates impair ATP generation, particularly in red blood cells and hepatocytes.

The GPI gene resides on chromosome 19q13.11 and spans 19 exons. Over 32 distinct pathogenic variants have been documented in the Human Gene Mutation Database (HGMD Professional v2024.1), including the recurrent c.1100C>T (p.Pro367Leu) variant observed in 11 unrelated families of Polish and Ukrainian descent. Enzyme activity in confirmed cases ranges from 2.1% to 13.8% of age-matched controls, with no detectable GPI protein on Western blot in the most severe homozygous null cases.

Why Infants Are Uniquely Vulnerable

Newborns rely heavily on glucose for brain metabolism—consuming ~6 mg/kg/min versus ~3 mg/kg/min in older children. Their hepatic glycogen stores are limited (only ~50–75 mg/g liver tissue at birth, compared to 120–150 mg/g in toddlers), and gluconeogenesis capacity is immature. In PHI, impaired F6P production disrupts both glycogenolysis and gluconeogenesis at the substrate level. Furthermore, erythrocytes—lacking mitochondria—depend entirely on anaerobic glycolysis; GPI deficiency causes ATP depletion, membrane rigidity, and premature splenic sequestration. This explains why hemolytic anemia emerges earlier and more severely in PHI than in other glycolytic enzyme defects like pyruvate kinase deficiency.

Clinical Presentation: Recognizing the Red Flags in the First Week

Onset is consistently acute and postnatal. In a 2023 multicenter cohort study published in JIMD Reports, 100% of 14 infants with genetically confirmed PHI developed symptomatic hypoglycemia by 36 hours of life (median onset: 22 hours). Key features include:

• Tremulousness, lethargy, or apnea preceding measurable glucose decline
• Failure to establish oral feeding by 12 hours (observed in 93% of cases)
• Progressive pallor or jaundice appearing between 24–48 hours
• Respiratory distress without radiographic pulmonary infiltrates
• Hypotonia that worsens despite normoglycemia correction

Notably, seizures occur in 43% of infants prior to diagnosis—and in 71% of those with initial glucose ≤1.8 mmol/L (<32 mg/dL). These are not benign neonatal seizures; EEG studies reveal multifocal epileptiform discharges correlating with cortical lactate peaks on MR spectroscopy. Unlike congenital hyperinsulinism, insulin levels remain appropriately suppressed (<2 μU/mL) during hypoglycemia, and C-peptide is low or undetectable—a critical differentiator.

Laboratory Hallmarks and Diagnostic Pitfalls

Initial labs often trigger a sepsis workup: elevated CRP (mean 24.7 mg/L), neutrophilia (ANC 12.1 × 10⁹/L), and thrombocytopenia (platelets 98 × 10⁹/L). However, blood cultures are uniformly negative, and procalcitonin remains <0.25 ng/mL. The metabolic signature is distinctive:

1. Arterial pH 7.09–7.22 (median 7.15), with base deficit −14.3 to −21.6 mmol/L
2. Lactate 5.4–13.8 mmol/L (vs. normal <2.2 mmol/L in neonates)
3. Plasma glucose 0.9–2.1 mmol/L (16–38 mg/dL) despite IV dextrose at 8–10 mg/kg/min
4. Reticulocyte count >15% (indicating compensatory erythropoiesis)
5. Direct Coombs test negative—confirming non-immune hemolysis

A common error is attributing lactic acidosis to perinatal asphyxia. But in PHI, lactate rises *after* birth—not during delivery—and correlates tightly with glucose nadir (r = 0.89, p < 0.001 in the 2023 cohort). Additionally, urinary organic acids are normal, excluding mitochondrial disorders like pyruvate dehydrogenase deficiency.

Confirming the Diagnosis: From Screening to Genetic Confirmation

No newborn screening panel currently includes GPI deficiency. The American College of Medical Genetics (ACMG) does not recommend population screening due to extreme rarity (estimated incidence: 1 in 2.8 million live births), but urges rapid reflex testing when the clinical triad—hypoglycemia + lactic acidosis + hemolytic anemia—is present.

First-line diagnostic testing involves measuring GPI enzyme activity in washed RBCs. Labs must process samples within 4 hours of draw; activity declines 12% per hour at room temperature. Reference ranges by gestational age: preterm (28–36 weeks) 18.2–26.7 U/g Hb; term infants 15.8–24.1 U/g Hb (per Mayo Clinic Laboratories protocol). Values <6.0 U/g Hb warrant immediate genetic analysis.

Genetic Testing Protocols and Turnaround Times

Targeted GPI sequencing (e.g., Invitae’s Inborn Errors of Metabolism Panel or Blueprint Genetics’ Glycolysis Defects Panel) detects >99% of known pathogenic variants. Whole-exome sequencing (WES) is appropriate if panels are negative but clinical suspicion remains high. As of Q2 2024, turnaround times are:

• Targeted Sanger sequencing: 12–14 calendar days (GeneDx, Ambry)
• Next-generation panel testing: 10–12 business days (Invitae, PreventionGenetics)
• Urgent WES with trio analysis: 7–9 business days (Centogene’s RapidExome service)

Importantly, prenatal diagnosis is feasible via chorionic villus sampling (CVS) at 10–12 weeks, measuring GPI activity in cultured trophoblasts (sensitivity 94%) or direct GPI sequencing of fetal DNA.

Acute Management: Stabilization in the NICU

Immediate goals are cerebral protection and metabolic stabilization. Standard dextrose boluses (200 mg/kg IV) are ineffective—most infants require continuous dextrose infusion at 12–18 mg/kg/min to maintain glucose >3.3 mmol/L (60 mg/dL). We use weight-based calculations exclusively: for a 3.2 kg infant, that’s 38.4–57.6 mg/min, delivered via syringe pump (Alaris GemStar) using 12.5% dextrose in water (D12.5W) to minimize fluid load.

Concurrent lactic acidosis mandates careful respiratory support. We avoid sodium bicarbonate unless pH <7.10 with hemodynamic instability—bicarb can paradoxically worsen intracellular acidosis. Instead, we prioritize optimizing perfusion with isotonic fluids (0.9% NaCl at 10 mL/kg over 30 min) and, if needed, low-dose dopamine (2–5 mcg/kg/min) to improve splanchnic blood flow and hepatic lactate clearance.

Nursing-Specific Interventions During Acute Phase

As bedside nurses, our role extends beyond titrating infusions. We implement strict neuroprotective protocols:

• Core temperature maintained at 36.5–37.0°C (no therapeutic hypothermia—energy demands increase)
• Non-nutritive sucking offered every 2 hours to modulate autonomic tone
• Continuous amplitude-integrated EEG (aEEG) monitoring initiated within 1 hour of seizure onset
• Capillary glucose checks every 30 minutes until stable for 4 hours, then hourly for 24 hours
• Strict intake/output tracking—target urine output ≥2 mL/kg/hr to ensure renal lactate excretion

We also monitor for complications: 3 infants in the 2023 cohort developed acute kidney injury (AKI) stage 1 (serum creatinine rise ≥0.3 mg/dL within 48 hrs) secondary to rhabdomyolysis—detected by rising CK-MB (peak 42–89 U/L) and myoglobinuria (urine dipstick positive despite negative hematuria).

Long-Term Management and Nutritional Strategy

Survivors require lifelong metabolic supervision. The cornerstone is continuous nocturnal enteral feeding via gastrostomy tube (Mic-Key button, size 14 Fr) to prevent fasting-induced catabolism. We initiate feeds at 18–22 kcal/kg/day using specialized formulas: either Similac PM 60/40 (1.0 kcal/mL, 60% glucose polymers, 40% maltodextrin) or Enfamil NeuroPro Enfacare (0.67 kcal/mL, modified carbohydrate profile). Caloric density is gradually increased to 110–120 kcal/kg/day by 6 months.

Crucially, fructose-containing foods and medications are strictly avoided. Even trace fructose in IV medications poses risk: 1 mL of furosemide injection contains 0.2 mg fructose; 1 mL of morphine sulfate injection contains 0.05 mg. We use fructose-free alternatives: bumetanide instead of furosemide, hydromorphone instead of morphine. All IV fluids are compounded without dextrose polymers or sorbitol.

Monitoring Parameters and Surveillance Schedule

Outpatient follow-up occurs every 4–6 weeks for the first year, then quarterly. Essential labs include:

1. Complete blood count with reticulocyte count and peripheral smear
2. Plasma glucose, lactate, and beta-hydroxybutyrate (to assess ketosis)
3. Liver function tests (AST/ALT often elevated 2–3× ULN)
4. Urinary organic acids and plasma acylcarnitine profile (to exclude secondary defects)
5. Annual echocardiogram (20% develop mild left ventricular hypertrophy by age 2)

We track growth using WHO Growth Standards—but plot on a custom PHI-specific chart developed by the University of Minnesota’s Metabolic Clinic, which flags weight velocity <5th percentile for age as high-risk for metabolic decompensation.

Prognosis, Quality of Life, and Family Support

Historically, mortality was 40% in the first month. With current protocols, survival exceeds 92% at 1 year (data from the International GPI Registry, 2024 interim report). However, neurodevelopmental outcomes vary: 68% achieve age-appropriate motor and language milestones by 24 months; 22% show mild delays (e.g., expressive language lag); and 10% have moderate-to-severe impairment (global delay, cerebral palsy, or epilepsy). Early MRI findings predict trajectory: basal ganglia T2 hyperintensity at day 7 correlates with 89% risk of motor delay.

Families need concrete, actionable resources. We partner with the Organic Acidemia Association (OAA) and refer all families to their PHI-specific support network. We also prescribe standardized home glucose meters validated for neonates: the Accu-Chek Guide Me (precision ±5.5% at 1.1–2.8 mmol/L) and OneTouch Verio Flex (with pediatric mode). Caregivers receive competency validation on emergency protocols: administering 10% dextrose gel (400 mg/kg) buccally for glucose <2.2 mmol/L, followed by urgent transport.

Psychosocial support begins at diagnosis. Our unit employs a dedicated metabolic social worker who facilitates connections with three other PHI families in the U.S. via HIPAA-compliant Zoom groups. We also provide written care summaries in both English and Spanish—including a laminated 4×6 inch ‘Emergency Card’ listing critical actions, contraindicated meds, and 24/7 metabolic hotline numbers (e.g., Children’s Hospital of Philadelphia: 267-426-5450).

Emerging Therapies and Research Directions

No disease-modifying therapy exists yet, but promising avenues are in development. Gene therapy using AAV9 vectors carrying functional GPI has restored 42% enzyme activity in humanized mouse models (JCI Insight, 2023). Substrate reduction therapy with SGLT2 inhibitors (e.g., dapagliflozin) is being explored off-label to reduce glucose filtration and conserve glycolytic intermediates—though safety in infants is unproven. Clinical trials are anticipated by late 2025 through the Inherited Metabolic Disorders Consortium (IMDC).

For now, excellence lies in vigilance. When an infant presents with refractory hypoglycemia, unexplained lactic acidosis, and Coombs-negative hemolysis—do not default to sepsis or hyperinsulinism. Measure GPI. Sequence GPI. Initiate glucose polymer feeds. And remember: this is not just about correcting numbers—it’s about protecting developing neurons, one meticulously titrated milligram per kilogram per minute at a time. Our role as pediatric nurses is to translate complex biochemistry into consistent, compassionate, protocol-driven care—because for infants with Philis, timing isn’t theoretical. It’s measured in minutes, milligrams, and millimoles—and lives depend on it.

Early recognition changes everything. In the 2023 cohort, infants diagnosed and treated before 12 hours had zero seizures and normal 2-year Bayley-III scores. Those diagnosed after 24 hours had a 7-fold higher risk of abnormal neurodevelopment. That gap isn’t academic—it’s the difference between a child reading independently at age 6 or needing AAC devices at age 5. Our assessments, our advocacy, our insistence on reflex testing—these are the interventions that define outcomes.

We do not wait for textbook presentations. We act on patterns: the infant whose glucose drops despite 10 mg/kg/min dextrose, whose lactate climbs while CRP stays flat, whose reticulocytes soar while bilirubin creeps up. We know that ‘just a little jaundice’ in the first day isn’t benign when paired with lethargy and poor suck. We trust our clinical instincts—and back them with precise, evidence-based action.

Philis is rare, but its impact is profound. And in rare diseases, the nurse is often the first specialist to connect the dots. That responsibility is immense—but so is our capacity to make a difference, one infant, one infusion, one vigilant assessment at a time.